The findings of this systematic review suggest that pharmacotherapeutic agents targeting the NO-sGC-cGMP pathway exhibit promising potential for improving pulmonary hemodynamics and mitigating dyspnea severity, potentially optimizing health-related quality of life in COPD patients with PH. Here, SGCB is linked to chronic obstructive pulmonary disease.